Multicomponent Synthesis, Binding Mode, and Structure–Activity Relationship of Selective Histone Deacetylase 6 (HDAC6) Inhibitors with Bifurcated Capping Groups
- 1 September 2020
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 63 (18), 10339-10351
- https://doi.org/10.1021/acs.jmedchem.9b01888
Abstract
The histone deacetylase 6 (HDAC6) is an emerging target for the treatment of cancer, neurodegenerative diseases, inflammation, and other diseases. Here, we present the multicomponent synthesis and structure-activity relationships of a series of tetrazole-based HDAC6 inhibitors. We discovered the hit compound NR-160 by investigating the inhibition of recombinant HDAC enzymes and protein acetylation. A co-crystal structure of HDAC6 complexed with NR-160 disclosed that the steric complementarity of the bifurcated capping group of NR-160 to the L1 and L2 loop pockets may be responsible for its HDAC6-selective inhibition. While NR-160 displayed only low cytotoxicity as single-agent against leukemia cell lines, it augmented the apoptosis induction of the proteasome inhibitor bortezomib in combination experiments significantly. Furthermore, a combinatorial high throughput drug screen revealed significantly enhanced cytotoxicity when NR-160 was used in combination with epirubicin and daunorubicin. The synergistic effect in combination with bortezomib and anthracyclines highlights NR-160´s potential in combination therapies.Keywords
Funding Information
- Deutsche Forschungsgemeinschaft (HA 7783/1-1)
- National Institutes of Health (GM49758)
- H2020 European Research Council (852222)
- Deutsche Krebshilfe (70112951)
- Deutsches Konsortium f?r Translationale Krebsforschung
- Forschungskommission (2018-04)
This publication has 46 references indexed in Scilit:
- HDAC6 as a target for neurodegenerative diseases: what makes it different from the other HDACs?Molecular Neurodegeneration, 2013
- iMOSFLM: a new graphical interface for diffraction-image processing withMOSFLMActa crystallographica. Section D, Structural biology, 2011
- Overview of theCCP4 suite and current developmentsActa crystallographica. Section D, Structural biology, 2011
- Clinical Toxicities of Histone Deacetylase InhibitorsPharmaceuticals, 2010
- Features and development of CootActa crystallographica. Section D, Structural biology, 2010
- PHENIX: a comprehensive Python-based system for macromolecular structure solutionActa crystallographica. Section D, Structural biology, 2010
- MolProbity: all-atom structure validation for macromolecular crystallographyActa crystallographica. Section D, Structural biology, 2009
- Doxorubicin CardiomyopathyCardiology, 2009
- Genetic dissection of histone deacetylase requirement in tumor cellsProceedings of the National Academy of Sciences of the United States of America, 2009
- Mice Lacking Histone Deacetylase 6 Have Hyperacetylated Tubulin but Are Viable and Develop NormallyMolecular and Cellular Biology, 2008